To evaluate the efficacy and safety of infliximab biosimilar CT-P13 in patients with active
Takayasu arteritis (TAK). In this single-center open-label trial, patients with active TAK …

Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK).
Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory …

Takayasu arteritis (TA) is a chronic large vessel vasculitis affecting predominantly the aorta
45 and its main branches, as well as the pulmonary arteries (1, 2). Of unknown origin (3) …

Objective. To analyse the efficacy and tolerance of infliximab in refractory Takayasu arteritis
(TA). Methods. French multicentre retrospective study that included patients with TA. Clinical …

Objectives To evaluate effectiveness and safety of infliximab dose escalation in Takayasu
arteritis (TAK) patients. To identify factors associated with refractoriness to standard-dose …

Objective Tumor necrosis factor (TNF) alpha and interleukin‐17 (IL‐17) are thought to be
involved in the pathogenesis of Takayasu arteritis (TAK), and TNF inhibitors (TNFi) are …

Objective To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-α, in
the treatment of Takayasu arteritis. Materials and methods We used infliximab at an initial …

Objectives. We analysed a large cohort of patients with Takayasu arteritis, seeking robust
clinical evidence for prolonged responses to tumour necrosis factor-α (TNF-α) and …

Objective: Although biologic agents are used in Takayasu arteritis (TAK), corticosteroids are
still the mainstay of treatment. This study aimed to investigate the feasible maintenance dose …

Objective To compare the treatment outcomes of TNF inhibitors and tocilizumab (TCZ) in
patients with Takayasu arteritis. Methods Takayasu arteritis patients who were refractory to …